Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.11779/850
Title: Comparison of Major-Bleeding Risk and Health Care Costs Among Treatment-Naïve Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban, or Warfarin
Authors: Amin, Alpesh
Keshishian, A
Xie, L
Başer, Onur
Price, K
Vo, L
Singh, P
Bruno, A
Mardekian, J
Tan, W
Singhal, S
Patel, C
Odell, K
Trocio J.
Source: Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Singh P, Bruno A, Mardekian J, Tan W, Singhal S, Patel C, Odell K, Trocio J. (November 7-11, 2015). Comparison of major-bleeding risk and health care costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin. American Heart Association (AHA) Scientific Sessions 2015. Orlando, FL.
Abstract: ...
Description: Onur Başer (MEF Author)
##nofulltext##
URI: https://hdl.handle.net/20.500.11779/850
Appears in Collections:Ekonomi Bölümü Koleksiyonu

Show full item record



CORE Recommender

Page view(s)

24
checked on Nov 18, 2024

Google ScholarTM

Check





Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.